Biblio

15 resultats trouvés
Filtres: Auteur is Lebray, Pascal  [Clear All Filters]
1
Houssel-Debry P, Coilly A, Fougerou-Leurent C, Jezequel C, Duvoux C, de Ledinghen V, Radenne S, Kamar N, Leroy V, Di Martino V et al..  2018.  12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. HEPATOLOGY. 68:1277-1287.
D
Hezode C, Lebray P, de Ledinghen V, Zoulim F, Di Martino V, Boyer N, Larrey D, Botta-Fridlund D, Silvain C, Fontaine H et al..  2017.  Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. LIVER INTERNATIONAL. 37:1314-1324.
Hezode C, de Ledinghen V, Fontaine H, Zoulim F, Lebray P, Boyer N, Larrey DG, Silvain C, Botta-Fridlund D, Leroy V et al..  2015.  Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. HEPATOLOGY. 62:314A.
Herve C, Coilly A, Fougerou-Leurent C, de Ledinghen V, Pageaux G-P, Houssel-Debry P, Radenne S, Duvoux C, Di Martino V, Kamar N et al..  2015.  Determinants and impact of early viral kinetics in patients with HCV-recurrence after liver transplantation treated by sofosbuvir plus daclatasvir: results from the ANRS CO23 CUPILT study. HEPATOLOGY. 62:209A.
H
Mouna L, Rossignol E, Tateo M, Coilly A, Duclos-Vallee J-C, Duvoux C, Durand F, Tran A, Radenne S, Canva-Delcambre V et al..  2019.  Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference. JOURNAL OF HEPATOLOGY. 70:1297-1300.
I
Coilly A, Pageaux G-P, Houssel-Debry P, Duvoux C, Radenne S, de Ledinghen V, Botta-Fridlund D, Vallet-Pichard A, Anty R, Di Martino V et al..  2015.  Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA? HEPATOLOGY. 62:257A.
L
Seree O, Altieri M, Guillaume E, De Mil R, Lobbedez T, Robinson P, Segol P, Salame E, Abergel A, Boillot O et al..  2018.  Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients. LIVER TRANSPLANTATION. 24:1425-1436.
M
Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V, Radenne S, Kamar N, d'Alteroche L, Leroy V et al..  2016.  Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study. JOURNAL OF HEPATOLOGY. 65:711-718.
N
Mouna L, Rossignol E, Tateo M, Duclos-Vallee J-C, Duvoux C, Durand F, Tran A, Radenne S, Canva-Delcambre V, Houssel-Debry P et al..  2017.  No evidence of hepatitis B virus reactivation among liver transplant recipients treated with interferon- free regimens for hepatitis C virus recurrence (ANRS CO23 CUPILT Cohort). HEPATOLOGY. 66:873A-874A.
P
Meunier L, Pageaux G-P, Radenne S, Pichard AVallet, Houssel-Debry P, Duvoux C, Fridlund DBotta, de Ledinghen V, Conti F, Anty R et al..  2019.  Patients treated for HCV and listed for LT in a French multicenter study: What happens at 3 years? JOURNAL OF HEPATOLOGY. 70:E741-E742.
R
Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, Radenne S, Coilly A, Garrigue V, d'Alteroche L et al..  2014.  Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. NEW ENGLAND JOURNAL OF MEDICINE. 370:1111–1120.
Kamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux GPhillippe, Barbet C, Moal V, Couzi L, Horvatits T, De Man RA et al..  2020.  Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. CLINICAL INFECTIOUS DISEASES. 71:1204-1211.
Altieri M, Seree O, Lobbedez T, Segol P, Abergel A, Blaizot X, Boillot O, Boudjema K, Coilly A, Conti F et al..  2021.  Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 45:101514.
S
Houssel-Debry P, Coilly A, Fougerou-Leurent C, Jezequel C, Duvoux C, de Ledinghen V, Radenne S, Kamar N, Leroy V, Di Martino V et al..  2016.  Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study.. HEPATOLOGY. 64:465A.
Dumortier J, Leroy V, Duvoux C, de Ledinghen V, Francoz C, Houssel-Debry P, Radenne S, d'Alteroche L, Fougerou-Leurent C, Canva V et al..  2016.  Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. LIVER TRANSPLANTATION. 22:1367-1378.